Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30456695 | 0.86 | KMT2A (0.38) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL1642605 | 0.81 | KMT2A (0.49) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL4760209 | 0.79 | KMT2A (0.47) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL17942384 | 0.79 | KMT2A (0.38) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL3145134 | 0.79 | KMT2A (0.48) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL26808118 | 0.78 | KMT2A (0.54) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27779605 | 0.78 | KMT2A (0.47) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL19347554 | 0.76 | POLB (0.56) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL19913410 | 0.76 | KMT2A (0.45) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL14816146 | 0.75 | ADORA2A (0.36) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704090-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260125363-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260108506-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED | 2026-04-23 | — | — | US | disclosed |
| US-20260092047-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMA (US) | 2026-04-02 | — | — | US | disclosed |
| US-12583824-B2 | 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity | GENZYME CORPORATION (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260034064-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | VERTEX PHARMA (US) | 2026-02-05 | — | — | US | disclosed |
| US-12415798-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-09-16 | — | — | US | disclosed |
| US-12384762-B2 | Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| US-12350262-B2 | Methods of treatment for cystic fibrosis | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4565212-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20090018131-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | ADAMS NICHOLAS D | 2009-01-15 | — | — | US | disclosed |
| WO-2008157191-A2 | QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-1965785-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. Organon (NL) | 2008-09-10 | — | — | EP | disclosed |
| CN-101223140-A | Piperidine derivatives useful in the diagnostic and therapeutic treatment of diseases depending on renin activity | NOVARTIS AG (CH) | 2008-07-16 | — | — | CN | disclosed |
| CN-101208299-A | Diarylsulfone sulfonamides and use therof | WYETH CORP (US) | 2008-06-25 | — | — | CN | disclosed |
| CN-100361992-C | Sulfonamide substituted xanthine derivatives for use as PEPCK inhibitors | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | CN | disclosed |
| WO-2007071638-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. ORGANON (NL) | 2007-06-28 | — | — | WO | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
| CN-1751044-A | Sulfonamide substituted xanthine derivatives for use as PEPCK inhibitors | HOFFMANN LA ROCHE (CH) | 2006-03-22 | — | — | CN | disclosed |
| CN-1617855-A | Cytosolic phospholipase A2Inhibitors | WYETH CORP (US) | 2005-05-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12350262-B2 | Methods of treatment for cystic fibrosis | CFTR, SLC26A4, SCNN1B | KMT2A 4340/4885MEN1 2938/4885POLB 1505/4885 |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | KMT2A 2785/4885MEN1 1433/4885POLB 4217/4885 |
| US-20260125363-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, SLC26A3 | KMT2A 3014/4885MEN1 1794/4885POLB 2643/4885 |
| US-20260108506-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, CLCN2, SCNN1B | KMT2A 3438/4885MEN1 4187/4885POLB 2703/4885 |
| US-12384762-B2 | Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | CFTR, SLC26A4, TMEM109 | KMT2A 4439/4885MEN1 3338/4885POLB 4282/4885 |
| US-12583824-B2 | 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity | CFTR, CLIC1, NHERF1 | KMT2A 4154/4885MEN1 3025/4885POLB 2858/4885 |
| US-20260092047-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | CFTR, SLC26A3, SLC26A4 | KMT2A 4757/4885MEN1 3673/4885POLB 3928/4885 |
| US-12415798-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SCNN1G | KMT2A 4813/4885MEN1 4316/4885POLB 3212/4885 |
| US-20260034064-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | CFTR, ABCC2, ABCC8 | KMT2A 1937/4885MEN1 2277/4885POLB 4619/4885 |
| US-20090018131-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | JAK3, PI4KA, AKT3 | KMT2A 3791/4885MEN1 1791/4885POLB 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.